UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2026

Anteris Technologies Global Corp.

(Exact name of registrant as specified in its charter)

Delaware	**001-42437**	**99-1407174**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

Toowong Tower, Level 3, Suite 302 **9 Sherwood Road** **Toowong, QLD** **Australia**	**4066**
(Address of Principal Executive Offices)	**(Zip Code)**

Registrant's telephone number, including area code: +61 7 3152 3200

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, par value $0.0001 per share	AVR	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure

On July 31, 2026, Anteris Technologies Global Corp. (the "Company") submitted the materials attached as Exhibits 99.1 and 99.2 to the Australian Securities Exchange. Trading on The Nasdaq Global Market is not impacted.

The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit No.	Description
99.1	Anteris Technologies Global Corp. (ASX:AVR) – Request for trading halt under ASX Listing Rule 17.1
99.2	ASX Announcement regarding certain regulatory matters relating to the issuance of CHESS Depositary Interests
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Anteris Technologies Global Corp.

Date: July 31, 2026

By:	/s/ Wayne Paterson
Name:	Wayne Paterson
Title:	Vice Chairman and Chief Executive Officer

Attention: Ms. Monique Burley
ASX Listings Compliance
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

By email: monique.burley@asx.com.au;
TradingHaltsPerth@asx.com.au

31 July 2026

Dear Ms. Burley,

Anteris Technologies Global Corp. (ASX:AVR) – request for trading halt under ASX Listing Rule 17.1

Pursuant to ASX Listing Rule 17.1, Anteris Technologies Global Corp. (the **Company**) requests a trading halt in the Company's securities from the commencement of trading on 31 July 2026.

In accordance with ASX Listing Rule 17.1, the Company advises:

- the trading halt is requested pending its consideration of an inadvertent non-lodgement of cleansing notices in relation to an issue of CHESS Depositary Interests in the Company (CDIs), within five business days of the issue of CDIs, in respect of which the Company intends to seek relief from the Federal Court of Australia (Relief Application);

- the trading halt is requested to apply until the earlier of such time the Company makes an announcement regarding the outcome of the Relief Application and the commencement of normal trading on ASX on 4 August 2026; and

- the Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market or ASX about the trading halt.

Yours sincerely,

/s/ Wayne Paterson

Wayne Paterson,
Vice Chairman and Chief Executive Officer
Anteris Technologies Global Corp.

Cleansing Notice Update

MINNEAPOLIS, United States and **BRISBANE, Australia July 31, 2026: Anteris Technologies Global Corp.** (**Anteris** or the **Company**) (NASDAQ: AVR, ASX: AVR) advises that on July 10, 2026, 44,068 CHESS Depositary Interests (**CDIs**) were issued following the exercise of certain November 2025 warrants. Due to an administrative oversight, a cleansing notice under section 708A(6) of the Corporations Act 2001 (Cth) (**Corporations Act**) was not lodged within the prescribed 5 business day period. Anteris intends to lodge a cleansing notice today in relation to the issue of the CDIs notwithstanding it is outside of the prescribed period.

Anteris understands the CDIs issued have been sold.

Anteris will submit an application to the Federal Court shortly seeking orders for relief under section 1322 of the Corporations Act and seeking an extension of time to lodge the cleansing notice, deeming it to be effective from the date of issue of the relevant CDIs.

The Company does not consider the oversight to be price sensitive and the Company did not possess excluded information (as defined in section 708A(7) of the Corporations Act) at the time of issue of the CDIs.

Anteris will keep the market informed as to the progress of the application.

Trading on The Nasdaq Stock Market is not impacted.

ENDS

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Chief Executive Officer.

For more information:

Global Investor Relations
investors@anteristech.com
Debbie Ormsby
Anteris Technologies Global Corp.
+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)
mchatterjee@bplifescience.com
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
+1 917 330 4269

Website	www.anteristech.com
X	@AnterisTech
LinkedIn	https://www.linkedin.com/company/anteristech